 Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under Janssen Collaboration with FT555 GPRC5D-targeted Product Candidate Demonstrate Robust and Durable Tumor Clearance in Highly Aggressive Myeloma Model SAN DIEGO, Dec. 10, 2022 GLOBE NEWSWIRE Fate Therapeutics, ... The post Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Progr... 